Omeros (OMER) Stock Rating Upgraded by ValuEngine

Share on StockTwits

Omeros (NASDAQ:OMER) was upgraded by ValuEngine from a “buy” rating to a “strong-buy” rating in a research note issued on Wednesday, ValuEngine reports.

OMER has been the subject of a number of other reports. Zacks Investment Research lowered Omeros from a “hold” rating to a “sell” rating in a research report on Wednesday, February 13th. HC Wainwright set a $34.00 target price on Omeros and gave the company a “buy” rating in a research report on Thursday, December 13th. Finally, Maxim Group set a $32.00 target price on Omeros and gave the company a “buy” rating in a research report on Thursday, December 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and two have given a strong buy rating to the stock. Omeros currently has an average rating of “Buy” and an average price target of $27.00.

Shares of Omeros stock opened at $18.35 on Wednesday. Omeros has a one year low of $10.30 and a one year high of $27.00. The stock has a market capitalization of $890.51 million, a P/E ratio of -8.27 and a beta of 3.60.

Omeros (NASDAQ:OMER) last issued its earnings results on Friday, March 1st. The biopharmaceutical company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.27. The firm had revenue of $22.02 million during the quarter, compared to the consensus estimate of $22.42 million. During the same period in the previous year, the firm earned ($0.34) earnings per share. The business’s quarterly revenue was up 60.0% on a year-over-year basis. On average, equities analysts anticipate that Omeros will post -0.3 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. grew its position in Omeros by 65.7% in the third quarter. JPMorgan Chase & Co. now owns 15,421 shares of the biopharmaceutical company’s stock valued at $376,000 after acquiring an additional 6,116 shares in the last quarter. BlackRock Inc. grew its position in Omeros by 1.0% in the third quarter. BlackRock Inc. now owns 3,957,936 shares of the biopharmaceutical company’s stock valued at $96,614,000 after acquiring an additional 38,349 shares in the last quarter. Allianz Asset Management GmbH grew its position in Omeros by 15.1% in the third quarter. Allianz Asset Management GmbH now owns 73,815 shares of the biopharmaceutical company’s stock valued at $1,802,000 after acquiring an additional 9,694 shares in the last quarter. Tocqueville Asset Management L.P. grew its position in Omeros by 24.7% in the third quarter. Tocqueville Asset Management L.P. now owns 23,700 shares of the biopharmaceutical company’s stock valued at $579,000 after acquiring an additional 4,700 shares in the last quarter. Finally, Man Group plc acquired a new stake in Omeros in the third quarter valued at approximately $286,000. 49.19% of the stock is owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Read More: Do closed-end mutual funds pay dividends?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Blockparty   Hits Market Cap of $1.78 Million
Blockparty Hits Market Cap of $1.78 Million
Zacks: Farmers & Merchants Bancorp, Inc.   Receives Consensus Rating of “Hold” from Analysts
Zacks: Farmers & Merchants Bancorp, Inc. Receives Consensus Rating of “Hold” from Analysts
-$0.18 EPS Expected for 2U Inc  This Quarter
-$0.18 EPS Expected for 2U Inc This Quarter
29,753 Shares in Halliburton  Acquired by Steinberg Global Asset Management
29,753 Shares in Halliburton Acquired by Steinberg Global Asset Management
Steinberg Global Asset Management Has $4.12 Million Stake in Lamar Advertising Co
Steinberg Global Asset Management Has $4.12 Million Stake in Lamar Advertising Co
iShares MSCI EAFE Small-Cap ETF  Shares Bought by Steinberg Global Asset Management
iShares MSCI EAFE Small-Cap ETF Shares Bought by Steinberg Global Asset Management


© 2006-2019 Ticker Report